Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Injection shortage
To Be Discontinued 1 presentations · 1 manufacturers · first FDA posting Sep 9, 2026 · last update Sep 9, 2026
Manufacturers: Merck Sharp & Dohme LLC
Stated reasons (per FDA): Not stated
More info: FDA Drug Shortages Database · ASHP drug shortages list (search there for this drug)
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02) | Merck Sharp & Dohme LLC | To Be Discontinued | — | To be discontinued on or near late September 2026. | Posted Sep 9, 2026 Updated Sep 9, 2026 Discontinued Sep 9, 2026 |